Evidence map›Paper›PMID 38722382›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.

Nourhan Shalaby, Ying Xia, John J Kelly, Rafael Sanchez-Pupo, Francisco Martinez, Matthew S Fox, Jonathan D Thiessen, Justin W Hicks, Timothy J Scholl, John A Ronald

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nourhan ShalabyDepartment of Medical Biophysics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. nshalaby@uwo.ca.ORCID 0000-0001-9264-7191
Ying XiaRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
John J KellyRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Rafael Sanchez-PupoRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Francisco MartinezRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Matthew S FoxLawson Health Research Institute, London, ON, Canada.
Jonathan D ThiessenRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Justin W HicksRobarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Timothy J SchollDepartment of Medical Biophysics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
John A RonaldDepartment of Medical Biophysics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

Funding

Non-Invasive Monitoring of CRISPR/Cas-Edited Chimeric Antigen Receptor T (CAR-T) Cells with Reporter Gene-Based Magnetic Resonance Imaging and Positron Emission TomographyUH2EB028907 · NIBIB · UNIVERSITY OF WESTERN ONTARIO · PI RONALD, JOHN ANDREW · 2019 to 2020
$323k
Natural Sciences and Engineering Research Council of Canada Natural Sciences and Engineering Research Council of CanadaNIBIB NIH HHS UH2 EB028907NIH HHS 1UH2EB028907-01Ontario Institute for Cancer Research Ontario Institute for Cancer Research
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) cell therapies utilize CARs to redirect immune cells towards cancer cells expressing specific antigens like human epidermal growth factor receptor 2 (HER2). Despite their potential, CAR T cell therapies exhibit variable response rates and adverse effects in some patients. Non-invasive molecular imaging can aid in predicting patient outcomes by tracking infused cells post-administration. CAR-T cells are typically autologous, increasing manufacturing complexity and costs. An alternative approach involves developing CAR natural killer (CAR-NK) cells as an off-the-shelf allogeneic product. In this study, we engineered HER2-targeted CAR-NK cells co-expressing the positron emission tomography (PET) reporter gene human sodium-iodide symporter (NIS) and assessed their therapeutic efficacy and PET imaging capability in a HER2 ovarian cancer mouse model.NK-92 cells were genetically modified to express a HER2-targeted CAR, the bioluminescence imaging reporter Antares, and NIS. HER2-expressing ovarian cancer cells were engineered to express the bioluminescence reporter Firefly luciferase (Fluc). Co-culture experiments demonstrated significantly enhanced cytotoxicity of CAR-NK cells compared to naive NK cells. In vivo studies involving mice with Fluc-expressing tumors revealed that those treated with CAR-NK cells exhibited reduced tumor burden and prolonged survival compared to controls. Longitudinal bioluminescence imaging demonstrated stable signals from CAR-NK cells over time. PET imaging using the NIS-targeted tracer 18F-tetrafluoroborate ([

Indexed as

Erb-b2 Receptor Tyrosine KinasesKiller Cells, NaturalOvarian NeoplasmsPositron-Emission TomographyReceptors, Chimeric AntigenSymportersAnimalsCell Line, TumorFemaleHumansMiceSodium-Iodide SymportersERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Chimeric AntigenSodium-Iodide SymportersSymportersBioluminescence imagingCellular therapyChimeric antigen receptor (CAR)HER2Natural killer (NK) cellsPositron emission tomography

Identifiers

PMID38722382
PMCPMC11368970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.